Skip to main content

Advertisement

SpringerLink
Log in

The Impact of Immunodeficiency on NK Cell Maturation and Function

  • Immune Deficiency and Dysregulation (Caroline Kuo, Section Editor)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

A Correction to this article was published on 07 March 2019

This article has been updated

Abstract

Purpose of Review

Natural killer cells are innate lymphoid cells (ILCs) that play critical roles in human host defense and are especially useful in combating viral pathogens and malignancy.

Recent Findings

The NK cell deficiency (NKD) is particularly underscored in patients with a congenital immunodeficiency in which NK cell development or function is affected. The classical NK cell deficiency (cNKD) is a result of absent or a profound decrease in the number of circulating NK cells. In contrast, functional NKD (fNKD) is characterized by abnormal NK cell function but with normal number of NK cells. The combined immune deficiencies with significant impact on NK cells are not considered classical or functional NK cell deficiencies. In these disorders, the impairment of NK cells represents an important aspect of the overall immunodeficiency. In turn, this leads to improved insights on the NK cell development and function.

Summary

Here, we detail the NK cell biology based upon recent natural killer cell defects described in combined immune deficiencies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 07 March 2019

    The section heading that reads PI3K100δ Deficiency should be corrected to read PI3K110δ Deficiency.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Mace EM, et al. Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest. 2017;127(1):306–20.

    PubMed  Google Scholar 

  2. •• Vargas-Hernandez A, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018;141(6):2142–2155 e5 This study shows that JAK inibition can partially rescue NK cell function in STAT1-GOF patients.

    CAS  PubMed  Google Scholar 

  3. Voss M, Bryceson YT. Natural killer cell biology illuminated by primary immunodeficiency syndromes in humans. Clin Immunol. 2017;177:29–42.

    CAS  PubMed  Google Scholar 

  4. Ham H, Billadeau DD. Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity. Front Immunol. 2014;5:2.

    PubMed  PubMed Central  Google Scholar 

  5. Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol. 2013;132(3):515–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Mace EM, Orange JS. Genetic causes of human NK cell deficiency and their effect on NK cell subsets. Front Immunol. 2016;7:545.

    PubMed  PubMed Central  Google Scholar 

  7. Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, Dropulic L, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood. 2013;121(14):2669–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. de Vries E, Koene HR, Vossen JM, Gratama JW, von dem Borne A, Waaijer JL, et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood. 1996;88(8):3022–7.

    PubMed  Google Scholar 

  9. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest. 2012;122(10):3769–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol. 1996;103(3):408–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood. 2010;115(8):1519–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Hsu AP, Sampaio EP, Khan J, Calvo KR, Lemieux JE, Patel SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Kazenwadel J, Secker GA, Liu YJ, Rosenfeld JA, Wildin RS, Cuellar-Rodriguez J, et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood. 2012;119(5):1283–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Dickinson RE, Griffin H, Bigley V, Reynard LN, Hussain R, Haniffa M, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood. 2011;118(10):2656–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Gineau L, Cognet C, Kara N, Lach FP, Dunne J, Veturi U, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest. 2012;122(3):821–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Hughes CR, Guasti L, Meimaridou E, Chuang CH, Schimenti JC, King PJ, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest. 2012;122(3):814–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Eidenschenk C, Dunne J, Jouanguy E, Fourlinnie C, Gineau L, Bacq D, et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet. 2006;78(4):721–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Cottineau J, Kottemann MC, Lach FP, Kang YH, Vély F, Deenick EK, et al. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest. 2017;127(5):1991–2006.

    PubMed  PubMed Central  Google Scholar 

  19. Eidenschenk C, Jouanguy E, Alcais A, Mention JJ, Pasquier B, Fleckenstein IM, et al. Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. J Immunol. 2006;177(12):8835–43.

    CAS  PubMed  Google Scholar 

  20. Etzioni A, Eidenschenk C, Katz R, Beck R, Casanova JL, Pollack S. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr. 2005;146(3):423–5.

    PubMed  Google Scholar 

  21. Lenart M, Trzyna E, Rutkowska M, Bukowska-Strakova K, Szaflarska A, Pituch-Noworolska A, et al. The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism. Int J Mol Med. 2010;26(3):435–42.

    CAS  PubMed  Google Scholar 

  22. Ilves I, Petojevic T, Pesavento JJ, Botchan MR. Activation of the MCM2-7 helicase by association with Cdc45 and GINS proteins. Mol Cell. 2010;37(2):247–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Fedick AM, Shi L, Jalas C, Treff NR, Ekstein J, Kornreich R, et al. Carrier screening of RTEL1 mutations in the Ashkenazi Jewish population. Clin Genet. 2015;88(2):177–81.

    CAS  PubMed  Google Scholar 

  24. Ballew BJ, Joseph V, de S, Sarek G, Vannier JB, Stracker T, et al. A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome. PLoS Genet. 2013;9(8):e1003695.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Ballew BJ, Yeager M, Jacobs K, Giri N, Boland J, Burdett L, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in dyskeratosis congenita. Hum Genet. 2013;132(4):473–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. James AM, Hsu HT, Dongre P, Uzel G, Mace EM, Banerjee PP, et al. Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling. Blood. 2013;121(14):2627–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Kohl S, et al. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J Immunol. 1984;133(6):2972–8.

    CAS  PubMed  Google Scholar 

  28. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LAB, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54–61.

    PubMed  Google Scholar 

  30. Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131(6):1624–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Toth B, et al. Herpes in STAT1 gain-of-function mutation [corrected]. Lancet. 2012;379(9835):2500.

    PubMed  Google Scholar 

  33. Tabellini G, Vairo D, Scomodon O, Tamassia N, Ferraro RM, Patrizi O, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2017;140(2):553–64 e4.

    CAS  PubMed  Google Scholar 

  34. Caldirola MS, Rodríguez Broggi MG, Gaillard MI, Bezrodnik L, Zwirner NW. Primary immunodeficiencies unravel the role of IL-2/CD25/STAT5b in human natural killer cell maturation. Front Immunol. 2018;9:1429.

    PubMed  PubMed Central  Google Scholar 

  35. •• Ruiz-Garcia R, et al. Mutations in PI3K110delta cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol. 2018;142(2):605–617 e7 PI3K110delta mutations impair natural killer cell function which can be partially rescued with rapamycin treatment.

    CAS  PubMed  Google Scholar 

  36. •• Salzer E, et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nat Immunol. 2016;17(12):1352–60 Cytoskeletal dynamics are essential to NK cell function. RASGRP1 deficient NK cells have decreased cytotoxicity.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. •• Dobbs K, et al. Natural killer cells from patients with recombinase-activating gene and non-homologous end joining gene defects comprise a higher frequency of CD56(bright) NKG2A(+++) cells, and yet display increased degranulation and higher perforin content. Front Immunol. 2017;8:798 RAG mutations can affect NK cell maturation leading to abnormal expression of developmental markers and NK inhibitory receptors.

    PubMed  PubMed Central  Google Scholar 

  38. Mossner R, et al. Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infect Dis. 2016;62(7):951–3.

    PubMed  Google Scholar 

  39. Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629–40 e2.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Hwa V, Camacho-Hübner C, Little BM, David A, Metherell LA, el-Khatib N, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68(5):218–24.

    CAS  PubMed  Google Scholar 

  41. Nadeau K, Hwa V, Rosenfeld RG. STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease. J Pediatr. 2011;158(5):701–8.

    CAS  PubMed  Google Scholar 

  42. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349(12):1139–47.

    CAS  PubMed  Google Scholar 

  43. Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K, Bezrodnik L, et al. Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol. 2006;177(5):2770–4.

    CAS  PubMed  Google Scholar 

  44. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics. 2006;118(5):e1584–92.

    PubMed  Google Scholar 

  45. Ma CA, Xi L, Cauff B, DeZure A, Freeman AF, Hambleton S, et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood. 2017;129(5):650–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009;206(1):25–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Mrozek E, et al. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood. 1996;87(7):2632–40.

    CAS  PubMed  Google Scholar 

  48. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3) K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97.

    CAS  PubMed  Google Scholar 

  50. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem. 1997;272(31):19236–41.

    CAS  PubMed  Google Scholar 

  51. Kok K, Nock GE, Verrall EAG, Mitchell MP, Hommes DW, Peppelenbosch MP, et al. Regulation of p110delta PI 3-kinase gene expression. PLoS One. 2009;4(4):e5145.

    PubMed  PubMed Central  Google Scholar 

  52. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci. 2009;34(3):115–27.

    CAS  PubMed  Google Scholar 

  53. Dornan GL, Siempelkamp BD, Jenkins ML, Vadas O, Lucas CL, Burke JE. Conformational disruption of PI3Kdelta regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc Natl Acad Sci U S A. 2017;114(8):1982–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597–606 e4.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Marti F, Xu CW, Selvakumar A, Brent R, Dupont B, King PD. LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1998;95(20):11810–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood. 2005;105(12):4722–9.

    CAS  PubMed  Google Scholar 

  57. Kanakaraj P, Duckworth B, Azzoni L, Kamoun M, Cantley LC, Perussia B. Phosphatidylinositol-3 kinase activation induced upon fc gamma RIIIA-ligand interaction. J Exp Med. 1994;179(2):551–8.

    CAS  PubMed  Google Scholar 

  58. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC. RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs. Science. 1998;280(5366):1082–6.

    CAS  PubMed  Google Scholar 

  59. Roose J, Weiss A. T cells: getting a GRP on Ras. Nat Immunol. 2000;1(4):275–6.

    CAS  PubMed  Google Scholar 

  60. Lee SH, Yun S, Lee J, Kim MJ, Piao ZH, Jeong M, et al. RasGRP1 is required for human NK cell function. J Immunol. 2009;183(12):7931–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Rivera-Munoz P, Malivert L, Derdouch S, Azerrad C, Abramowski V, Revy P, et al. DNA repair and the immune system: from V(D) J recombination to aging lymphocytes. Eur J Immunol. 2007;37(Suppl 1):S71–82.

    CAS  PubMed  Google Scholar 

  62. Lee YN, Frugoni F, Dobbs K, Tirosh I, du L, Ververs FA, et al. Characterization of T and B cell repertoire diversity in patients with RAG deficiency. Sci Immunol. 2016;1(6):eaah6109.

    PubMed  PubMed Central  Google Scholar 

  63. Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016;16(4):234–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Niehues T, Perez-Becker R, Schuetz C. More than just SCID—the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2. Clin Immunol. 2010;135(2):183–92.

    CAS  PubMed  Google Scholar 

  65. Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. Science. 1996;274(5284):97–9.

    CAS  PubMed  Google Scholar 

  66. Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al. Partial V(D) J recombination activity leads to Omenn syndrome. Cell. 1998;93(5):885–96.

    CAS  PubMed  Google Scholar 

  67. de Villartay JP, Lim A, al-Mousa H, Dupont S, Déchanet-Merville J, Coumau-Gatbois E, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115(11):3291–9.

    PubMed  PubMed Central  Google Scholar 

  68. Ehl S, Schwarz K, Enders A, Duffner U, Pannicke U, Kühr J, et al. A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest. 2005;115(11):3140–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Felgentreff K, Perez-Becker R, Speckmann C, Schwarz K, Kalwak K, Markelj G, et al. Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency. Clin Immunol. 2011;141(1):73–82.

    CAS  PubMed  Google Scholar 

  70. Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358(19):2030–8.

    CAS  PubMed  Google Scholar 

  71. De Ravin SS, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116(8):1263–71.

    PubMed  PubMed Central  Google Scholar 

  72. Henderson LA, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132(4):969–71 e1-2.

    CAS  PubMed  Google Scholar 

  73. Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2016;126(11):4389.

    PubMed  PubMed Central  Google Scholar 

  74. Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol. 2014;133(4):1099–108.

    CAS  PubMed  Google Scholar 

  75. Notarangelo LD, Mazzolari E. Natural killer cell deficiencies and severe varicella infection. J Pediatr. 2006;148(4):563–4 author reply 564.

    PubMed  Google Scholar 

  76. Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, Hsu AP, Zerbe CS, Calvo KR, et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood. 2011;118(13):3715–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Genovese P, Schiroli G, Escobar G, di Tomaso T, Firrito C, Calabria A, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014;510(7504):235–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Kuo CY. Advances in site-specific gene editing for primary immune deficiencies. Curr Opin Allergy Clin Immunol. 2018;18:453–8.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge Dr. Emily Mace, for her critical review of the manuscript.

Funding

Chao Physician Scientist Junior Faculty Award, Baylor College of Medicine

Author information

Authors and Affiliations

  1. Department of Pediatrics, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, USA

    Alexander Vargas-Hernández & Lisa R. Forbes

  2. Center for Human Immunobiology, William T Shearer Center for Human Immunobiology, Texas Children’s Hospital, 1102 Bates Ave, Suite 330, Houston, TX, 77030, USA

    Alexander Vargas-Hernández & Lisa R. Forbes

Authors
  1. Alexander Vargas-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa R. Forbes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa R. Forbes.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Immune Deficiency and Dysregulation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vargas-Hernández, A., Forbes, L.R. The Impact of Immunodeficiency on NK Cell Maturation and Function. Curr Allergy Asthma Rep 19, 2 (2019). https://doi.org/10.1007/s11882-019-0836-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-019-0836-8

Keywords

Search

Navigation